German hematology research association specializing in leukemia, lymphoma, and blood cancer real-world patient data within Europe's HARMONY platform.
ERIC CLL (European Research Initiative on Chronic Lymphocytic Leukemia) is a Cologne-based scientific association specializing in hematological malignancies — particularly leukemia, lymphoma, and related blood cancers. Their core contribution is providing clinical expertise and real-world patient data to large collaborative research platforms aimed at improving outcomes for patients with blood cancers. In both H2020 projects, they served as a subject-matter contributor within the HARMONY consortium, Europe's largest big data platform for hematological malignancies. Their work bridges clinical oncology practice with data science, helping translate registry-level patient data into actionable findings for medicine and health policy.
Both HARMONY and HARMONY PLUS projects directly address leukemia, lymphoma, myelodysplastic syndromes, multiple myeloma, and childhood cancer — the exact disease areas ERIC CLL was established to study.
HARMONY focused specifically on real-life patient data and a Big Data platform for hematological malignancies, with ERIC CLL as a contributing node.
HARMONY PLUS (2020-2024) introduced translational medicine and molecular genetics keywords, reflecting a move from data aggregation toward clinical application.
HARMONY PLUS keywords include 'digital health outcome' and 'business model', signaling involvement in sustainability and value frameworks for health data platforms.
From 2017 to around 2020, their work centered on identifying and categorizing disease types (leukemia, lymphoma, myelodysplastic syndromes, multiple myeloma) and contributing real-world patient data to a shared big data infrastructure. In the second phase (2020–2024), the focus shifted toward what to do with that data — molecular genetics, translational medicine, digital health outcomes, and even business modeling entered the picture. The trajectory is clear: they moved from data contributor to active participant in turning aggregated patient data into clinical and commercial value.
ERIC CLL is evolving from a disease-specific data source into an organization with capabilities in translational medicine and digital health value chains, making them increasingly relevant for projects at the intersection of oncology data and health technology development.
ERIC CLL has participated exclusively as a consortium partner — never as coordinator — across both projects, both within the same HARMONY family of initiatives. This points to a focused specialist role: they bring deep disease-area knowledge and patient data access rather than project management capacity. Their placement within a 57-partner, 13-country consortium suggests they are comfortable operating as one expert node among many in large European research alliances.
ERIC CLL has built connections with 57 unique consortium partners spanning 13 countries, all through the HARMONY ecosystem — one of the largest hematology data alliances in Europe. Their network is concentrated rather than broad: deep ties within one major consortium rather than spread across many independent collaborations.
ERIC CLL occupies a narrow but high-value niche: they are a disease-specific research association dedicated to CLL and related blood cancers, with established access to European-level patient data infrastructure through HARMONY. For any consortium building a project around hematological malignancies, rare blood disorders, or oncology real-world evidence, they offer both scientific credibility and a ready connection to a pan-European patient data network. Their registered association structure (eingetragener Verein) in Germany gives them non-profit legitimacy that can strengthen ethics and governance sections of grant applications.
